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1. Introduction  
Over 33 million people worldwide are infected with human immunodeficiency virus type 1 
(HIV-1). In addition, over 2.7 million new cases are diagnosed each year with half of these 
infections occurring in individuals younger than 25 years (UNAIDS, 2008). Fortunately, 
since the emergence of highly active antiretroviral therapy (HAART) in 1996, morbidity and 
mortality associated with HIV-1 infection have been markedly decreased. HIV-1 infected 
patients have demonstrated dramatic decreases in viral burden and opportunistic infections, 
and an overall increase in life expectancy. Despite the positive HAART-associations 
outcomes, including the improvement of the clinical course, prognosis, and survival of 
patients infected with HIV-1, it has become increasingly clear that HIV-1 infected patients 
have an enhanced risk for developing noninfectious consequences of HIV-1 infection over 
time. In the last few years, lipodystrophy, characterized by redistribution of body fat, and 
insulin resistance, have been reported in many HIV-1 infected patients, and their 
relationship with antiretroviral drugs and HIV-1 infection per se have become a subject of 
debate and researches worldwide. Evidence suggests that HIV-1 infected patients are under 
chronic oxidative stress that may be involved in the development and progression of the 
disease. Oxidative stress is enhanced by the chronic inflammation that is associated with 
activation of lymphocytes and phagocytes, and is accompanied by the direct or indirect 
effects of several opportunistic pathogens. In addition, HIV-1 proteins and various 
components of current HAART regimes contribute to oxidative stress-induced disturbances 
such as cardiovascular disease (including metabolic syndrome and endothelial dysfunction), 
neurological disorders (HIV-1 dementia), and ocular complications (retinopathy). 
Cardiovascular complications are been recognized with increasing frequency and are 
associated with the greatest risk of death in HIV-1 patients. Studies demonstrated that not 
only do various components of HAART contribute to endothelial cell damage and vascular 
dysfunction in patients, but also the viral proteins themselves increase cardiovascular risk. 
HIV-1-associated cardiovascular disease progression is thus most likely a multifactorial 
process, resulting from a combination of distinct HIV-1 proteins as well as various 
components of current multidrug antiretroviral therapy (Kline et al., 2008).  
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It is estimated that one-third of adults infected with HIV-1 develop dementia (Janssen et al., 
1992). It was reported that oxidative stress has been demonstrated in the brain and 
cerebrospinal fluid (CSF) from HIV-1 infected individuals, showing important implications 
for therapeutic approaches for HIV-1-induced dementia (HIVD).                 
The aim of this chapter is to review the roles of both HIV-1 proteins and antiretroviral drugs 
in the development of oxidative stress-induced disturbances such as cardiovascular disease 
and neurological disorders. For this purpose, studies, in vitro and in vivo, were identified by 
a systematic search through PubMed for English-language literature, included original and 
review articles published up to 2011.  
2. Oxidative stress and biomarkers 
Oxidative stress is defined as an imbalance between the antioxidant and pro-oxidant 
systems with the shift towards the pro-oxidant system. Oxidative stress is also defined as 
the modification and accumulation of biological molecules altered by various kinds of 
reactive oxygen species (ROS) and reactive nitrogen species (RNS). ROS and RNS affect 
gene transcription and cell growth/proliferation, and they have been considered 
intercellular signal molecules.  
ROS and RNS are highly reactive, toxic oxygen or nitrogen moieties, respectively, such 
hydroxyl radical, peroxyl radical, superoxide anion, hydrogen peroxide, nitric oxid (NO), 
and peroxynitrite. The half-life of ROS species varies from nanoseconds for the hydroxyl 
radical to seconds for NO and peroxyl radicals. Because of the differences in half-lives, the 
ROS reactivity differs from the aqueous environment in which they were formed to reacting 
deep within the membrane (Pocernich et al., 2005).   
In biological systems, the cellular membrane constitutes in a main target of the ROS and 
RNS. In addition to the cellular membrane, other intracellular membranes are important 
target of the oxidative stress such as mitochondrial, nuclear and endoplasmic reticulum 
membranes that can suffer the lesive action of the ROS and RNS by changing their form and 
function. Not only enzymes but also receptors and transport proteins can be important early 
targets of oxidative damage. While most ROS do not diffuse more than a few femtometres 
(fm), the lipid peroxides that are resulted from the ROS-induced peroxidation of membrane 
phospholipids, such as malondialdehyde (MDA), can transverse the circulation and cell 
membranes, with resultant dysfunction of vital cellular processes including membrane 
transport and mitochondrial respiration (Haliwell, 1987).  
ROS can attack double bonds in polyunsaturated fatty acids (PUFAs), inducing lipid 
peroxidation (LPO), which may result in more oxidative cellular damage. LPO has been 
defined as the oxidative deterioration of polyunsaturated lipids and its measurement is a 
laboratorial approach for determining oxidative stress. Peroxides and aldehydes generated 
are not only passive biomarkers of oxidative stress, but also cytotoxic products (Zwart et al., 
1999).  
MDA is a three carbon, low molecular weight aldehyde that can be produced from free 
radicals that attack on PUFAs of biological membranes. The determination of MDA is used 
for monitoring LPO in biological samples. LPO has been the focus of attention in recent 
researches because it was commonly thought that the thiobarbituric acid (TBA) test, the 
commonest assay of LPO in vitro, measures free MDA.  It arises largely from peroxidation of 
PUFAs with more than two double bonds, such as linolenic, arachidonic and 
docosahexaenoic acids. MDA can also be formed enzimatically during eicosanoid 
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metabolism. Under physiological conditions, proteins are more readily attacked by MDA 
than are free amino acids, resulting in modification of several residues, especially lysine, as 
well as intra- and intermolecular protein cross-links.  
One particular class of toxic products of LPO is the isoprostanes, a series of prostaglandin-
like compounds formed during peroxidation of arachidonic acid. Because they are 
structurally similar to prostaglandin F2ǂ, isoprostanes are collectively referred as F2-
isoprostane. F2-isoprostane is useful marker of LPO and can be measured in human plasma 
and urine (Halliwell & Gutteridge, 1999).  
Collectively, ROS can lead to oxidation of proteins, and DNA, peroxidation of lipids, and 
ultimately cell death (Butterfield et al., 2001). These protein carbonyl moieties result from 
a direct oxidation of many amino acids such as lysine, arginine, histidine, proline and 
threonine, -scission of the peptide backbone, or from binding of the LPO product 4-
hydroxy-2-nonenal (HNE) to proteins. Alterations in proteins can lead to aggregation, 
changes in secondary and tertiary structure, susceptibility to proteolysis, fragmentation, 
and loss-of function. LPO produces large amounts of aldehydes, such as HNE, MDA, and 
acrolein, and leads to isoprostanes formation (Butterfield et. al, 2002). HNE and acrolein 
contribute to membrane damage and cell death induced by various oxidative insults, and 
through alterations of protein structure, these molecules are capable of inhibiting DNA, 
RNA, and protein synthesis, glycolysis, and degradation of enzymes (Pocernick et al., 
2005).  
ROS produce a multiplicity of change in proteins, including oxidation of –SH groups, 
hydroxylation of thyrosine and phenylalanine, conversion of methionine to its sulphoxide 
and generation of protein peroxides. Several assays for damage to specific amino acid 
residues in proteins have been developed and can be used to assess steady-state levels of 
oxidative protein damage in vivo. The carbonyl assay is a general approach for evaluating 
oxidation protein damage. It is based on the fact that several ROS attack amino acid residues 
in proteins that results products with carbonyl groups, which can be measured after reaction 
with 2,4-dinitrophenylhydrazine (Halliwell & Gutteridge, 1999). Oxidative stress also 
increases the levels of protein oxidation measured by the Advanced Oxidation Protein 
Products (AOPPs). AOPPs are novel biomarkers of oxidative damage and are considered as 
reliable markers to estimate de degree of oxidant-mediated protein damage. AOPPs resulted 
from the interaction between oxidants and plasma proteins with the oxidation of amino acid 
residues such as tyrosine, leading to the formation of dityrosine-containing protein cross-
linking products detected by spectrophotometry (Witko-Sarsat et al., 1998). Neutrophils that 
constitute the most important source of chlorined oxidants due to their high content in 
myeloperoxidase might be involved in plasma AOPPs formation. In vivo plasma levels of 
AOPPs closely correlate with level of dityrosine, a hallmark of oxidized proteins, and with 
pentosidine, a marker of protein glycation closely related with oxidative stress (Witko-Sarsat 
et al., 1998).     
2.1 NO and HIV-1 infection  
NO is a free-radical gas, a diffusible messenger that displays a variety of physiological 
functions, including vasorelaxation, bronchodilatation, inhibition of platelet aggregation, 
and neurotransmission (Radi, 2004). Additionally, it appears to be involved in the 
macrophage-dependent killing of intracellular parasites and functions as a tumoricidal and 
antimicrobial molecule in vitro and in vivo (Torre et al., 2002). NO represents an important 
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component of the host immune response against DNA and RNA viral infections, including 
HIV-1 infection (Mannick et al., 1995). 
NO is synthesized by the family of enzymes called nitric oxide synthase (NOS). Various 
isoenzymes of NOS, such as endothelial nitric oxide synthase (eNOS), inducible NOS 
(iNOS), and neuronal NOS (nNOS) are localized in endothelium, macrophages, and the 
brain, respectively. In normal endothelial cells, the amino acid L-arginine is constitutively 
converted to L-citrulline and NO by eNOS.  
The iNOS expression is increased by oxidative stress or pro-inflammatory cytokines 
(Nathan, 1997). However, interleukin 1 beta (IL-1ǃ), interleukin 6 (IL-6), interferon alfa-2b 
(IFN-2b), interferon gamma (IFN-), and interleukin 17 (IL-17) induce iNOS, whereas 
transforming growth factor beta (TGF-), interleukin 4 (IL-4), interleukin 10 (IL-10), 
interleukin 11 (IL-11), and interleukin 13 (IL-13) suppress the induction of NO released from 
macrophages (Torre et al., 2002). In addition, HIV-1 also stimulates NO production by 
human macrophages, inasmuch as concentration of recombinant gp120 HIV-1 envelope 
glycoprotein in vitro increases production of NO by human monocyte-derived macrophages 
(Pietraforte et al., 1994).   
The excessive production of NO by iNOS may contribute to tissue damage in several 
inflammatory and infectious diseases and this damage may be the price to pay for 
equipping so many host cells with the ability to deploy this compound against infections. 
Although NO production can be increased by the iNOS, the biodisponibility of NO can be 
impaired because NO is consumed in a reaction with superoxide anion yielding a strong 
oxidant species, the peroxynitrite (ONOO-), which in turn accelerates the LPO reaction (Li et 
al., 2007; Tao et al., 2007). Peroxynitrite production is also supported by the elevated levels 
of nitrotyrosine, a marker of endogenous peroxynitrite generation found in both human and 
animal models (Yamaguchi et al., 2006). 
Since NO is a very labile free radical with a half-life of only a few seconds and is rapidly 
oxidized by tissue oxygen to the stable end products, nitrite (NO2-) and nitrate (NO3-), it is 
difficult to measure NO levels in the tissue directly with real time. NO can be evaluated by 
several methods, including the assessment of NO metabolite (NOx) levels. Commonly, 
serum NO levels are assessed on the basis of nitrite and nitrate concentration according to 
the Griess reaction supplemented by the enzymatic reduction of nitrate to nitrite with 
cadmium (Guevara et al., 1998; Navarro-Gonzales et al., 1998). Following up the changes in 
nitrite/nitrate levels in the human tissues and plasma samples can be an important tool in 
understanding NO involvement.   
Although NO is an important mediator of the immune response against microorganisms, 
NO that is produced during the infectious diseases may be also deleterious, particularly in 
HIV-1 infection where may contribute to AIDS pathogenesis by enhancing viral replication 
in lymphocytes (Jimenez et al., 2001) and monocytes (Blond et al., 2000), increasing 
lymphocyte apoptosis (Mossalayi et al., 1999), and participating in the pathogenesis of 
AIDS-related dementia complex (Adamson et al., 1996). A study demonstrated impaired 
iNOS mRNA expression and NO levels in peripheral blood mononuclear cells from HIV-1 
infected patients, either in vivo or in vitro HIV-1 infection of normal cells (Cairoli et al., 2008). 
Low levels of NO have been implicated in lymphocyte activation and proliferation (Barbul 
et al., 1990). NO donors such as sodium nitroprusside and to a lesser degree gaseous NO, 
increase lymphocyte uptake of glucose (an early event during lymphocyte activation), 
stimulate TNF- production and the transcriptional nuclear factor kappa beta (NF-kB) 
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binding activity, and enhance activity of tyrosine kinase, p56, which is implicated in 
lymphocyte signaling events (Lander et al., 1993). Paradoxically, high concentrations of NO, 
which occur following macrophage activation, suppress antigen presenting cell activity and 
T cell proliferation (Holt et al., 1991).    
In addition, vascular dysfunction and damage have been shown to be associated with 
impaired endothelial NO metabolism and function. Therefore, iNOS-derived NO mediates 
the inflammatory response and has been shown to cause vascular dysfunction in a number 
of experimental models (Gunnett et al., 2003).  
The data of NO levels obtained in HIV-1 infected individual samples are controversial. 
Groeneveld et al. (1996) have shown that serum nitrate concentrations are higher in 
asymptomatic HIV-1 infected patients than in healthy individuals. In addition, increased 
production of NO was correlated with RNA-HIV-1 viral load and activation of mononuclear 
phagocytes in HIV-1 infected patients. Torre et al. (1996a, 1996b) have shown that NO 
production is increased in AIDS patients with opportunistic infection, whereas nitrite 
concentrations were normal in asymptomatic patients. These authors have also confirmed 
increased production of NO and IL-1ǃ, TNF-ǂ, and IFN-Ǆ in the sera of children with HIV-1 
infection and they postulated that the increase in the concentration of these cytokines may 
represent a substantial stimulation of NO production. Zangerle et al. (1995) noted high 
nitrite and nitrate concentrations in 39 patients with AIDS without opportunistic infections, 
especially in those with lower CD4+ T cell counts, whereas in asymptomatic patients no such 
increase was seen. However, a previous study showed no altered endogenous nitrate 
formation in eight patients with AIDS, most of whom had opportunistic infections (Evans et 
al., 1994). 
However, some aspects must be taken in to account when these apparent controversial 
results are discussed including the fact that the oxidative stress was evaluated in HIV-1 
infected individuals that differed in the clinical course of the disease and in the presence or 
absence of opportunistic infections. Increases in the NO production may not be observed 
due the consume resources by the oxidative stress. Anyway, further studies may be 
necessary to confirm these previous results.  
2.2 Antioxidants 
To neutralize the damaging oxidative stress, natural antioxidant systems have evolved, 
including enzymes like glutathione (GSH) peroxidase, glutathione reductase, glutathione 
transferase, superoxide dismutase (SOD), S-methyl transferase, and catalase. Protection 
against free radicals can also come from small non-protein, cellular antioxidants, 
nonenzymatic, such as vitamin C, vitamin E, carotenoids, flavonoids, thioredoxin, and uric 
acid (Butterfield, et al., 1997).  
GSH is a tripeptide ( glutamate-cysteine-glycine) present in high concentrations in all 
mammalian cells that has many critical protective and metabolic functions. GSH detoxifies 
electrophilic metabolites of xenobiotics and protects cells from the toxic effects of free 
radicals and ROS (Bleuter, 1989). It is also important in the immune response against 
infections and plays an important role in lymphocyte proliferation, antibody-dependent and 
cell-mediated cytotoxicity, and protection of lymphocytes against superoxides that are 
produced to destroy invading pathogens (Droge et al., 1991; Smyth, 1991). N-acetyl-L-
cysteine (NAC) acts as an indirect precursor of GSH by raising levels of cysteine, a precursor 
of GSH. Whey proteins have been shown to increase GSH levels in human, most likely by 
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supplying the amino acid cysteine necessary for the synthesis of GSH (Pocernich et al., 
2005).    
Vitamin C represents the major water-soluble antioxidant in the human body. Ascorbate 
protects cell components from free radical damage by quenching water soluble radicals, 
scavenging lipid-peroxidation-derived radicals, or reducing tocopherol radical to tocopherol 
(Stehbens, 2004).  
SOD is an endogenous antioxidant that catalyses de dismutation of the superoxide anion 
radical (Stambullian et al., 2007).  
Vitamin E, a potent chain breaking lipid soluble antioxidant, reacts with lipid peroxyl 
radical eventually by terminating the peroxidation chain reaction and thereby by reducing 
oxidative damage. Vitamin E acts as an antioxidant on biomembranes and it is the principal 
lipid soluble chain-breaking antioxidant in mitochondria, microsomes, and lipoproteins.  
Selenium is an essential nonmetal trace element that is necessary for normal immune 
function. Selenium also increases the GSH peroxidase activity and its deficiency diminishes 
cell-mediated immunity and depresses B-cell function (Stehbens, 2004).  
3. Evidences of oxidative stress in individuals infected with HIV-1 
The hallmark of HIV-1 infection is the cellular CD4+ T cell immunodeficiency; however, the 
real cause of the loss of these cells is unknown. The most widely accepted hypothesis is that 
HIV-1 primes the cell to apoptotic death. Different agents appear to trigger apoptosis in 
CD4+ T cells, including viral protein, inappropriate secretion of inflammatory cytokines by 
activated macrophages and toxins produced by opportunistic microorganisms. Since 
oxidative stress can also induce apoptosis, it can be hypothesized that it could participate in 
CD4+ T cell apoptosis observed in AIDS (Reppeto et al., 1996). 
Evidence suggested that HIV-1 infected patients are under chronic oxidative stress. This 
effect is subsequent to depletion of endogenous antioxidant moieties and to an increased 
production of ROS.  Observation of the multiple pathogenic interactions between ROS and 
the HIV-1 has drawn attention to the possibility that these types of the interaction may play 
a role in the pathogenesis of many other viruses as well. ROS has been suggested to be 
involved in many aspects of HIV-1 disease pathogenesis, including increase viral 
replication, inflammatory response, decrease of immune cell proliferation, loss of immune 
function, chronic weight loss, and increase sensitivity to drug toxicity. In addition, 
antiretroviral combination therapy increases protein oxidation as well as the level of 
oxidative stress already present in HIV-1 infection (Ngondi et al., 2006). 
One aspect of the role of ROS in HIV-1 pathogenesis is the positive modulatory effect on the 
immune activation, important both in eradication of viral infection but also in immune-
induced cellular injury (Schwarz, 1996). HIV-1 infections causes a chronic inflammation as 
shown by high plasma levels of pro and inflammatory cytokines, chemokines and ROS in 
seropositive individuals (Israel & Gougerot-Pocidalo, 1997). Increased production of ROS 
such as superoxide anion, hydroxyl radical, and hydrogen peroxide may be related to an 
increased activation of polymorphonuclear leukocytes during HIV-1 infection or influenced 
by the pro-oxidant effect of pro-inflammatory cytokines produced by activated 
macrophages during the course of HIV-1 infection (Das et al., 1990) 
In HIV-1 infected patients, the increased oxidative stress has been implicated in increased 
HIV-1 transcription through the activation of NF-kB. NF-kB is bound to kinase inhibitor 
nuclear factor-kB (IkB) in the cytoplasm in its active form, but various factors, such as TNF-
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 and ROS, can cause the release of NF-kB from factor IkB, and NF-kB translocates to the 
nucleus and binds to DNA. In this way, the NF-kB is available to bind in the nuclear DNA 
and to induce HIV-1 gene transcription (Schereck et al., 1991). Thus, oxidative stress may 
potentially be involved in the pathogenesis of HIV-1 infection through direct effects of cells 
and through interactions with NF-kB and activation of HIV-1 replication (Greenspan & 
Aruoma, 1994; Israel & Gougerot-Pocidalo, 1997). 
The activation of phagocytes induced by HIV-1 is associated with oxidative stress, not only 
because ROS are released but also the fact that activated phagocytes may release pro-
oxidant cytokines, such as TNF- and IL-1, which promote iron uptake by the monocyte 
macrophage system. TNF- is synthesized in infected host cells, produces pro-oxidant 
effects in mitochondria, and inhibits mitochondrial respiration at Site II, the site of 
superoxide production (Schulze-Osthoff et al., 1992). Other cytokine that is involved in the 
oxidative stress is the IL-1. Activated monocytes produce IL-1 that stimulates neutrophils to 
release lysosomal proteins, including lactoferrin. This protein rapidly binds iron and this 
complex accumulates in the monocyte macrophage system. If the accumulated iron exceeds 
cellular iron-binding capacity, unbound pro-oxidant iron could interact with the superoxide 
via Fenton’s reaction and produces hydroxyl radicals (Halliwell, 1987).     
Oxidative stress biomarkers (pro-oxidants and antioxidants) have been investigated in HIV-
1 patients serum samples; however, previous studies show inconsistent findings regarding 
MDA levels in these patients. One study showed significantly elevated serum MDA 
concentration in HIV-1 infected patients, where HIV-1 symptomatic presented higher levels 
than asymptomatic patients, suggesting that the infection results in oxidative stress of the 
host lipids (Sönnerborg et al., 1988; Jordão Júnior et al. 1998; Suresh et al., 2009). The 
oxidative stress was evaluated by the LPO and GSH plasma levels in 150 HIV-1 infected 
individuals and in 30 healthy controls, and the results showed that the mean LPO plasma 
levels were significantly higher in HIV-1 infected individuals as compared to healthy 
controls, and the mean GSH level in HIV-1 infected individuals was significantly lower 
compared to healthy controls. In addition, there was a significant positive correlation 
between absolute CD4+ T cells and GSH levels. However, there was no significant difference 
in the levels of LPO and GSH among HIV-1 infected individuals receiving antiretroviral 
therapy (ART) and those without ART (Wanchu et al., 2009).  
Jordão Júnior et al. (1998) evaluated 28 serologically positive HIV-1 patients, 16 patients 
with AIDS (with < 200/mm3 CD4+T lymphocytes) and 12 HIV-1 infected and asymptomatic 
patients (with 200-500/mm3 CD4+ T lymphocytes). The control group consisted of 11 
healthy individuals. All individuals showed normal plasma vitamin A levels. However, 
urinary excretion of vitamin A and MDA was higher in AIDS patients than in HIV-1 
asymptomatic patients and considerably higher than in the control subjects. Therefore, the 
severe oxidative stress that occurs in the HIV-1 seropositive patients in comparison with 
seronegative individuals can exert a role in the progression of disease (Suresh et al., 2009)  
4. Oxidative stress and cardiovascular diseases associated with HIV-1 
infection 
Endothelium dysfunction is an initial step in the development of cardiovascular diseases, 
especially atherosclerosis, and is associated with an increase in oxidative stress. HIV-1 
infection is associated with increased ROS production and chronic oxidative stress, 
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suggesting a role of ROS in HV-1-induced endothelial cells dysfunction. Evidence from 
experimental, observational, and clinical studies suggests that HIV-1 infection itself and the 
associated pro-inflammatory response can increase the risk of cardiovascular disease.  
Multiple mechanisms, both specific and overlapping ways, are proposed to explain how 
HIV-1 proteins damage the endothelium, considering that viral genome contains nine 
main genes (gag, pol, env, tat, rev, vpu, vpr, vif, and nef) and encodes for approximately 15 
mature HIV-1 proteins that may interact with any number of unique targets. Proteolytic 
cleavage of the Gag-Pol precursor protein yields the major structural components of the 
viral core including matrix p17, capsid p24, nucleocapsides p9 and p6, reverse 
transcriptase (RT), protease and integrase. Proteolytic cleavage of Env produces the 
important envelope glycoprotein (gp) gp120 and gp41. The remaining genes encode for 
the regulatory proteins Tat and Rev, and the accessory proteins Vpu, Vpr, Vif, and Nef 
(Greene, 1991).   
The gp120, Tat, Vpu, and Nef proteins exert some important effects on endothelial cell 
homeostasis (reviewed by Kline & Sutliff, 2008). HIV-1 proteins can activate several 
inflammatory pathways in the vascular wall with cytokines release and expression of 
endothelial molecules, such as vascular cell adhesion molecule-1 (VCAM-1), intracellular 
adhesion molecule-1 (ICAM-1), and E-selectin (Seigneur et al., 1997; Greenwood et al., 1998; 
Wolf et al. 2002). The gp120 increases the expression of ICAM-1, but not VCAM-1 or E-
selectin, in human coronary artery, lung, brain, umbilical vein, and dermal microvascular 
endothelial cells. The gp120 also induces the apoptosis in human coronary endothelial cells, 
the adhesion of monocytes and lymphocytes to the endothelium; gp120 increases the 
endothelium permeability through cytoskeletal rearrangement, downregulation of tight 
junction proteins, and increases ROS production. The gp120 negatively affects endothelium 
function through the production of potent vasoconstrictors. The nonstructural Tat protein 
contains 86-101 amino acids that are formed from two exons. The first exon contributes to 
the first 72 amino acids and acts as a transacting nuclear regulatory protein actively secreted 
by infected cells that is essential for viral replication. 
Similar to gp120, Tat protein can promote the apoptosis, monocyte chemoattraction and 
adhesion, endothelium permeability, proliferation, angiogenesis, and an increase in the 
expression of matrix metalloproteinases and ROS. It has been demonstrated that viral Tat 
protein liberated by HIV-1 infected cells interferes with calcium homeostasis, activates 
caspases and induces mitochondrial generation and accumulation of ROS, all being 
important events in the apoptotic cascade of several cell types. When activated, peripheral 
blood T lymphocytes are induced to express Fas/APO-1/CD95 receptor that mediates 
apoptosis when binding to Fas ligand. CD4+ T cell subset depletion in HIV-1/AIDS patients 
is the most dramatic effect of apoptosis mediated by redox abnormalities and induction of 
Fas/APO-1/CD95 receptor expression (Westendorp et al., 1995; Kruman et al., 1998; 
Jaworowski & Crowe, 1999). 
In patients with uncontrolled HIV-1 infection, vasculitis are also observed in small blood 
vessels, aneurysms in medium and large arteries, significantly decreased levels of high-
density lipoprotein (HDL) cholesterol, and elevated plasma levels of von Willebrand factor, 
plasminogen activator inhibitor-1 (PAI-1) antigen, and tissue-type plasminogen activator 
(tPA). Although HIV-1 is likely not vasculotropic, the virus affects endothelium homeostasis 
and function in important ways (Kline & Sutliff, 2008).  
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The vascular endothelium is exposed continually to a number of viral stimuli in the 
bloodstream. These stimuli include: a) HIV-1 infected CD4+ T cells, monocytes, and 
macrophages; b) freely circulating HIV-1 viruses; c) HIV-1 proteins released upon host cell 
lysis; d) actively secreted proteins (Tat and gp120); and e) viral-induced pro-inflammatory 
cytokines. HIV-1-induced cytokines may also activate the endothelium, leading to enhanced 
production of ROS, and the release of chemoattractant at localized areas of vascular 
inflammation. HIV-1-infected individuals have higher plasma levels of hydroperoxides and 
MDA compared with uninfected individuals, indicating enhanced ROS-mediated LPO. 
HIV-1-induced ROS likely contribute to endothelium dysfunction through direct effects on 
the endothelium and/or indirectly through monocytes and macrophages contacting the 
vessel wall.  
Elevated ROS in HIV-1 infection could play a role in various signaling pathways, among 
which are the mitogen-activated protein kinases (MAPKs). MAPKs are serine and threonine 
protein kinases, which have three major classes, including extracellular signal-regulated 
kinase 1 and 2 (ERK1/2) and BMK1, c-Jun N-terminal protein kinases (JNKs) and p38. ROS 
may mediate activation of MAPKs in a variety of cells, leading to changes in gene 
expression (Blenis, 1993), downregulation of eNOS, and alteration of other gene expression 
involved in the endothelium dysfunction. Taken together, these data indicate that oxidative 
stress activating MAPKs, may be one of the major mechanisms in HIV-1-induced 
endothelium dysfunction.  
HIV-1 infected patients have low circulating levels of the antioxidant vitamin C, cysteine, 
and GSH, a situation that can lead to increased oxidative stress. Serum GSH levels and GSH 
peroxidase activity are decreased in HIV-1 patients, while the LPO product MDA, DNA 
fragmentation in lymphocytes, and total hydroperoxides are increased. These observations 
have important implications for therapeutic approaches. Clinical studies showed that 
selenium, and  carotene supplementation increased serum GSH levels. Dual vitamin C and 
E supplementation reduced plasma LPO and oxidative stress in HIV-1 patients. 
Supplementation with -tocopherol or selenium also decreased plasma viral load and 
improved T-cell numbers and viability (Suresh et al, 2009; Stehbens, 2004).   
These clinical findings suggest that vascular endothelial cells are exposed to ROS in the form 
of LPO products, pro-inflammatory cytokines, activated monocytes and phagocytes of the 
immune system.  
5. Oxidative stress associated with antiretroviral therapy 
Nearly 25 antiretroviral drugs have been licensed for the treatment of HIV-1 infected 
individuals and are divided mechanistically into five classes (reviewed by Estrada & 
Portilla, 2011): (1) nucleoside reverse transcriptase inhibitor (NRTI), including abacavir 
(ABC), didanosine (ddI), stavudine (d4T), lamivudine (3TC), tenofovir (TDF), zidovudine 
(AZT), and emtricitabine (FTC); (2) non-nucleoside reverse transcriptase inhibitor (NNRTI), 
including nevirapine (NVP), efavirenz (EFV), and etravirine (ETR); (3) protease inhibitor 
(PI) including atazanavir (ATV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), 
ritonavir (RTV), saquinavir (SQV), darunavir (DRV), fosamprenavir (FPV), and amprenavir 
(APV); (4) fusion inhibitor, entry inhibitor (chemokine receptor CCR5 inhibitor) including 
enfuvirtide and maraviroc (MVC); and (5) integrase inhibitor, including raltegravir (RAL).   
The HAART for management of HIV-1 infection that includes an association of the two 
NRTIs plus NNRTI and/or PI has been effective to suppress HIV-1 replication.  
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In addition to HIV-1 proteins, the HAART has been related with endothelium dysfunction. 
Experimental evidence shows that NRTIs are associated with endothelial cell toxicity. NRTIs 
induce oxidative stress, particularly mitochondrial ROS and seem to play an important role 
in cell culture and animal models of endothelial cell toxicity. However, clinical evidence for 
NRTIs-induced vascular/endothelium toxicity is indirect and difficult to define because 
NRTIs are not prescribed as monotherapy, and cardiovascular effects are often attributed to 
other components of HAART, such as PIs.  
NNRTIs show, in general, the best lipid profile of all anti –HIV-1 drugs because they are 
associated with an increase in HDL cholesterol and a significant reduction in cholesterol 
total/HDL ratio. NNRTIs have been associated with a lower risk of myocardial infarction 
(Worm et al., 2010) that could hypothetically be associated with this good lipid profile. As 
regard NVP, the mechanism of HDL elevation may be an increase in the production of 
apolipoprotein-A1 (Franssen et al., 2009).  
Among the PIs, lopinavir/ritonavir (LVP/r), DRV/r and ATV alone or with RTV (ATV/r) 
are the most extensively used PIs at present. PIs-associated dyslipidemia is a frequent class-
related event and can limit their use especially in patients with preexisting increase 
cardiovascular risk. A meta-analysis of major clinical trials performed in 2009 (Hill et al., 
2009) showed that patients randomized to LPV/r or FPV/r presented greater elevations of 
total cholesterol and triglycerides than those assigned to SQV/r, ATV/r, or DRV/r, without 
differences in low density lipoprotein cholesterol (LDL) or HDL.     
The integrase inhibitor RAL is the first drug in this class and shows a remarkable lack of 
relevant adverse effects (Emery et al., 2010) and patients treated with RAL presented a 
significantly low frequency of dyslipidemia (Martinez et al., 2010). 
Trials with HIV-1 patients treated with chemokine receptor-5 antagonist MVC have shown 
that it has a very favorable safety profile. MCV was associated with non-significant changes 
in total cholesterol, LDL, HDL and triglycerides (Cooper et al., 2010).     
The LDL receptor (LDLR) plays a critical role in the regulation of plasma LDL levels (Brown 
& Goldstein, 1986). By controlling LDL catabolism, the number of hepatic LDLR directly 
governs the plasma LDL concentrations. The expression of LDLR is under metabolic, 
hormonal, and genetic control. Growth hormone (GH), insulin, estrogen, and 
dehydroepiandrosterone (DHEA) may stimulate LDLR expression and reduce plasma LDL 
cholesterol levels (Wade et al., 1989; Pascale et al., 1995; Rudling et al., 1996). As important 
hormonal modifications occur in HIV-1 infected patients with lipodystrophy, particularly 
insulin and DHEA changes, the LDLR expression was evaluated in HIV-1 infected patients 
with or without lipodystrophy. The results revealed that HIV-1-lipodystrophy is associated 
with a low expression of LDLR and this decreased expression seems independent of DHEA 
or insulin secretion (Petit et al., 2002). These authors suggested that the decreased expression 
of the LDLR may be explained by a direct effect of the PIs (Rayes et al., 1996). Other 
hypothesis is that PIs lead to dyslipidemia by inhibition of LDLR-related protein (LRP), 
which has homology to the catalytic site of HIV-1 protease, to which all PIs bind (Carr et al., 
1998).   
The HIV-1 infected patients with lipodystrophy have also an impaired metabolism of DHEA 
and insulin, all known to regulate LDLR (Meyer et al., 1998; Walli et al., 1998; Christeff et al., 
1999; Behrens et al., 1999;). In addition, HIV-1 PIs also can modulate the function of certain 
LDLR family members. Tran et al., (2003) demonstrated that among six different HIV-1 PIs 
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evaluated, NFV, specifically, decreased mRNA and protein levels of the LDLR and LRP, 
which, in turn, decreased the functional activity of these two receptors. One study showed 
that  exposure of IDV or NFV, combined with AZT and EFV, increased ICAM-1 gene 
expression and that concomitant exposure to TNF- further increased ICAM-1 gene 
expression, VCAM-1, and endothelial-leukocyte adhesion molecule cell surface protein 
levels (Mondal et al., 2004).  
The Figure 1 shows the production of NO induced by HIV-1 and its viral proteins (mainly 
gp120 and Tat proteins), and by PIs in promoting beneficial and deleterious effects in the 
host cells. The NO is synthesized via MAPK signaling pathway when the macrophage is 
activated by pro-inflammatory and inflammatory cytokines as result of the HIV-1 infection. 
Despite the protective effect of NO in the host defense against this pathogen, NO has been 
associated with a harmful effect in many systems. 
The Figure 2 summarizes some of the effects of ROS and RNS that are induced by HIV-1 
proteins and PIs.  
 
 
 
 
 
Fig. 1. Mechanisms of nitric oxide (NO) production induced by human immunodeficiency 
virus type 1 (HIV-1) and the viral proteins (mainly gp120 and Tat proteins), and by protease 
inhibitors (PIs) in promoting beneficial and deleterious effects in the host cells. TNF-: 
tumor necrosis factor alpha;  
TNF-R: tumor necrosis factor alpha receptor; IL-1: interleukin 1; IL-1R: interleukin 1 
receptor; IFN-: interferon gamma; IFN-R: interferon gamma receptor; IL-6: interleukin 6; 
IL-6R: interleukin 6 receptor; IL-10: interleukin 10; IL-4: interleukin 4; TGF-: transforming 
growth factor beta; IFN-/: interferon alpha and interferon beta; MAPK: mitogen-activated 
protein kinase; IkB: kinase inhibitor nuclear factor-kB; transcriptional nuclear factor kappa 
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beta (NF-kB);  iNOS: inducible nitric oxide synthase; mRNA: messenger RNA; NO: nitric 
oxide.    
 
 
Fig. 2. Beneficial and deleterious effects of the endogenous reactive oxygen species (ROS) 
and reactive nitrogen species (RNS) that are induced by both human immunodeficiency 
virus type 1 (HIV-1) proteins  and the antiretroviral therapy with protease inhibitors (PIs). 
ROS and RNS that are accumulated by the imbalance of oxidants and antioxidants 
molecules exert effects on DNA, lipids, proteins,  signaling pathways, immune system cells, 
neuronal tissue, and endothelial functions. ERK1/2: extracellular signal-regulated kinase 1 
and 2; MAPKs: mitogen-activated protein kinases; transcriptional nuclear factor kappa beta 
(NF-kB). 
6. Molecular mechanisms of HIV-1 PI-induced endothelium dysfunction 
It is well-known that the endothelium acts as the first-line defense mechanism against the 
development of vascular injury. It exerts is protective action through modulation of vascular 
tone, vascular structure, and the interaction of blood components. Endothelial dysfunction 
may contribute to the systemic manifestations of many diseases, including atherosclerosis. 
Several reviews have been focused on metabolic disorders such as systemic insulin 
resistance, dyslipidemia, and peripheral lipodystrophy associated with endothelial 
dysfunction (Shankar & Dube, 2003; Koutkin & Grinspoon, 2004).  
The molecular mechanisms of PIs toxicity in endothelial cells have been described in greatly 
detail. The effect of PIs on endothelium-depending vasorelaxation was first suggested by the 
significant reduction of flow-mediated vasodilatation of the brachial artery in HIV-1 
infected patients receiving PIs as compared with the patients without PIs treatment (Stein et 
al., 2001). Other study showed that RTV, APV, or SQV individually caused a significant 
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reduction in endothelium-dependent vasorelaxation of porcine coronary arteries (Conklin et 
al., 2004).  The expression of eNOS was significantly decreased in porcine coronary arteries 
treated by RTV, SQV, and APV. In parallel, RTV also caused a significant reduction of eNOS 
messenger RNA (mRNA) and protein levels in cultured human coronary artery endothelial 
cells (Fu et al., 2005).      
PIs produces serious mitochondrial disturbances as evidenced by reduced cellular 
respiration and ATP production, decrease mitochondrial membrane potential, increase 
mitochondrial production of ROS, and enhanced mitochondrial DNA (mtDNA) damage. PIs 
also increase endothelial cell permeability and leukocyte adhesion in cell culture models. PIs 
contribute to cardiovascular risk by dysregulating fat cell homeostasis that may explain the 
high incidence of lipodystrophy and hyperlipidemia in HIV-1 patients. PIs prevent the 
differentiation of preadipocytes by decreasing matrix metalloproteinase expression, 
inhibiting adiponectin secretion, and inhibiting triglyceride and very low-density 
lipoprotein (VLDL) cholesterol clearance and catabolism (Wang et al., 2007). Evidences point 
to adipocytes as a complex and active endocrine tissue whose secretory products, including 
adiponectin, play an important role in the regulation of human metabolic alterations and 
vascular biology (Hamdy, 2005). Adiponectin accounts for approximately 0.01% of total 
plasma protein and has been shown to be related to lipodystrophy, metabolic alterations, 
and HIV-1 PIs use. Unlike other adipocyte products, adiponectin correlates with decreased 
free fatty acid blood concentrations and reduced body mass index. Adiponectin provides 
protection from vascular diseases by inhibiting local inflammatory signals, preventing 
preatherogenic plaque formation, and impeding arterial wall thickening (Schondorf et al., 
2005). However, HIV-1 PIs such as RTV selectively decreased expression of adiponectin 
(Kim et al., 2006) suggesting that hypoadiponectinemia is partially responsible for the 
metabolic disorders induced by HIV-1 PIs, and adiponectin or its agonists might be used for 
the treatment of these disorders (Xu et al., 2004) .          
HIV-1 PIs may also activate different types of MAPKs in different cell types or different 
culture conditions (Wang et al., 2007), leading to changes in gene expression in the same 
manner of the HIV-1 induced ROS. 
Some studies have showed high oxidative stress among the effects of HAART. Mandas et al. 
(2009) assessed serum oxidant and antioxidant levels in HIV-1 infected population treated 
with HAART and compared them with those untreated HIV-1 seropositive and HIV-1 
seronegative individuals. Serum oxidant levels were significantly higher in the HIV-1 
treated group as compared to untreated and control groups. In addition, a decrease of 
serum total antioxidant status was observed in HIV-1 treated individuals. An important 
result obtained is that patients who rigorously followed antiretroviral therapy have 
significantly higher oxidative status than those who have poor HAART adherence. These 
results indicate that HAART may affect oxidative stress in HIV-1 infected patients and also 
suggested that antiretroviral therapy may exert a synergic effect with HIV-1 in the oxidative 
stress induction.  
Another study (Gil et al., 2010) evaluated the effect of two HAART combinations on redox 
indicators and on progression markers of disease. A cohort of 84 healthy and 84 HIV-1 
seropositive subjects was followed for six months. Fifty-six HIV-1 seropositive subjects were 
distributed in group I (AZT, 3TC, IND) and group II (d4T, 3TC, NEV) according to drug 
combination. Biomarkers of oxidative stress were evaluated including peroxidation 
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potential (PP), MDA, total hydroperoxides (HPO), AOPP and, percent of DNA 
fragmentation (% FDNA). There were also evaluated biomarkers of antioxidant status, 
including catalase, SOD and GSH at baseline and six months after HAART started. In this 
study, the concentration of antioxidants was low at baseline, and LPO index and DNA 
fragmentation were increased. After HAART had been started, catalase values for both 
groups receiving treatment showed no significant difference. For group II, all other 
parameters of oxidative stress were significantly higher than those for group I and the HIV-
1 positive not treated, except for GSH values in group II which was lower than group I 
values. These data suggest poor prognostic for group II. The findings suggest that increased 
oxidative stress occurs additionally to persistent redox imbalance associated to HIV-1 
infection during apparently successfully HAART. 
HAART may increase chemically reactive species in circulation, possibly by producing more 
oxidized metabolites derived from the interaction between ROS and infected-cell 
biomolecules. This is supported by several biochemical mechanisms, such as mitochondrial 
interference, following treatment with HAART-NRTI and activation of the P450 hepatic 
system by HAART, when comprising PIs (La Asuncion et al., 1998; Kumar et al., 1999; 
Hulgan et al., 2003; Lewis, 2003; Cossarizza & Moyle, 2004; Day & Lewis, 2004). 
7. Oxidative stress in HIV-1 infection associated with neurological disorders 
The mechanisms by which HIV-1 first enters in the central nervous system (CNS) remain 
obscure. However, loss of blood-brain-barrier (BBB) integrity may be an important part of 
some of the tissue damage that accompanies HIV-1 infection of the brain, and may facilitate 
viral entry into the CNS. The active replication of HIV-1 into macrophages and microglia 
represents a reservoir for the virus and an important step for the neuropathogenesis of HIV-
1 infection. This process leading to the production of inflammatory products and, in turn, to 
the production of an excess formation of free radical species, is involved in the subsequent 
increased permeability of the BBB and has been suggested to play a key role in the 
neuropathogenesis of HIV-1 infection. The combination of BBB damage and elevated 
plasma viral load is associated with neurocognitive impairment and an increased risk for 
development of HIV-1-induced dementia (HIVD). In addition, oxidative stress has been 
demonstrated in the brain and cerebrospinal fluid (CSF) from HIV-1-infected individuals 
and it is proposed to be a key event in the pathophysiology of HIVD.  
One of the neurotoxins that is suggested to be involved in neuronal damage is NO. NO is a 
nitrogen free radical generates in many tissues, including the CNS, via bioconversion of L-
arginine into L-citrulline by nNOS (Lamas et al., 1998). It can be released constitutively by 
neurons in response to many neurochemical stimuli, including excitatory neurotransmission 
and changes of Ca2+ influx (Moncada et al., 1991).  NO release has been induced in vitro from 
glial cells following the addition of inflammatory cytokines and soluble antigens such as the 
HIV-1 coating gp120 glycoprotein (Dawson et al., 1993; Mollace & Nistico, 1995). Pro-
inflammatory cytokines including IL-1, TNF-, and IFN- which are released in HIV-1 
infected brain tissue have been shown to upregulate the iNOS. To modulate this response, 
the NO formation is downregulated by the cytokines tissue grown factor beta (TGF-), and 
IFN alpha/beta (IFN-/), according to Hua et al., (1998).   
Evidences show that although the direct neurotoxic effects of NO are modest, they are 
greatly enhanced by reacting with superoxide anion to form peroxynitrite. Superoxide anion 
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is produced by myeloid-monocytic cell lines following HIV-1 infection and the production 
of this molecule results in subsequent changes in the antioxidant status of these cells because 
SOD, a superoxide anion scavenger, is generated. Neurofilament, a protein that provides 
structural stability to neurons, is one of the target proteins of peroxynitrite and the resulting 
nitration results in disrupted neurofilament assembly and thus neuronal damage (Coyle & 
Puttfarcken, 1993).       
Neurotoxic levels of ROS and RNS are especially produced by the macrophages recruited to 
the CNS as well as by astrocytes and glial cells activated following different stimuli such as 
cytokine, endotoxin, and soluble antigens in the CSN.  
In vitro studies show that gp120 and Tat HIV-1 proteins can be directly toxic to human 
endothelial cells, compromises BBB integrity by reducing tight junction (occludin) protein 
expression and enhances monocytes migration across BBB. Protein oxidation was increased 
in the CSF of HIV-1 patients with mild and severe dementia compared to non-dement HIV-1 
patients. Nitrated tyrosine residues, evidence of peroxynitrite reaction with proteins, are 
increased in brain of HIVD patients. Activation of cytokine receptors and oxidative stress 
can induce the production of ceramide from membrane sphingomyelin, and recent findings 
suggest that ceramide is an important mediator of apoptosis. The HIV-1 Tat protein can also 
induce increase of ceramide and sphingomyelin in culture neurons. Tat can be transported 
efficiently across the intact BBB. In HIV-1 infected astrocytes, the regulatory gene tat is 
overexpressed, and mRNA levels for Tat protein are elevated in brain extracts from 
individuals with HIVD. The Tat sequences from brains of patients with HAD are mutated 
with glutamate substitutions in the second exon, which may decrease its ability to be taken 
up by cells, thus increasing its extracellular concentrations and possibly neurotoxicity effects 
in the cell. Brain regions particularly susceptible to Tat toxicity are striatum, hippocampal 
dentate gyrus, and the CA3 region of the hippocampus.  
Tat has been hypothesized by many studies as a potential contributor to HIVD by many 
mechanisms (reviewed by Pocernich et al., 2005). Tat protein released by astrocytes 
produces trimming of neuritis, mitochondrial dysfunction, and cell death in neurons. Tat- 
induced neurotoxicity is though to be mediated through excitotoxic mechanisms involving 
calcium. Tat can also induce markers of oxidative stress such as protein and LPO in 
synaptosomal membranes and neuronal cell cultures. To neutralize the oxidative stress, the 
GSH protects neurons against ROS directly and indirectly, and binds LPO products. GSH is 
the major cellular thiol participating in the maintenance of cellular redox status of the 
neuron and neuronal mitochondria. The biosynthesis of GSH may be compromised by Tat 
protein. It was hypothesized that the chronic inflammation of CSN by HIV-1, the activation 
of microglia, and increased lipid and protein oxidation, all observed in HIV-1 infected 
patients, can lead to the decrease of GSH serum levels and potentially HIVD. Low serum 
level of GSH is associated with poor survival in HIV-1-infected patients, while 
administration of GSH to HV-1-infected patients decreases mortality.  
The production of superoxide anions by HIV-1 infected cells is counteracted by SOD, which, 
in turn, generates hydrogen peroxide (H2O2). Under basal conditions this is scavenged by 
catalase. To date, clear evidence exists that catalase activity is modified in brain tissue of 
AIDS patients. However, it has recently been reported that catalase is diminished in CD8+ T 
lymphocytes from HIV-1 positive individuals, suggesting the H2O2 scavenger activity might 
be decreased during HIV-1 infection (Yano et al., 1998).      
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8. Antioxidant status in HIV-1 infection  
Although the concentration of plasma antioxidant components can be measured 
individually, these measurements may be time- and cost-consuming and labor intensive. In 
addition, it may not accurately reflect the total antioxidant status (Wayner et al., 1987).  Total 
antioxidant capacity considers the cumulative effect of all oxidants present in blood and any 
fluids (Nagy et al., 2006) and it could be evaluated by several assays including total peroxyl 
radical trapping antioxidant parameter (TRAP), total antioxidant capacity (TAC), ferric 
reducing ability (FRAP), and their variations. 
It has been previously shown that the HIV-1 infected individuals are oxidative stressed and 
have significantly lower antioxidant concentrations than HIV-1 seronegative individuals.  
There is experimental evidence that different metabolic events that occur as consequence of 
HIV-1 infection directly influence the consumption of antioxidant components thus 
contributing to the increase of oxidative stress. Studies have found impaired antioxidant 
defense in HIV-1 infected patients and the antioxidant depletion indicates a decrease in 
immune function. Cells of immune system generally require a higher antioxidant 
concentration than other cells to retain redox balance, and preserve integrity and function 
(De La Fuente et al., 2002). 
There are numerous studies reporting GSH deficiency in HIV-1 infection. The concentration 
of GSH is low in plasma, lung epithelial lining fluid, and peripheral blood mononuclear 
cells of HIV-1 infected individuals (Buhl et al., 1989; Roederer et al., 1993). Studies in vitro 
have shown that low GSH levels impair T cell function and also promote HIV-1 expression, 
suggesting a link between GSH deficiency and progression of HIV-1 disease (Kalebic et al., 
1991; Roederer et al., 1993). Poor survival rates of HIV-1 seropositive individuals with low 
GSH levels and improved survival when GSH was replenished were also reported 
(Herzenberg et al., 1997). Taken together, these data can proposed that a persistent oxidative 
stress leads an accelerated rate of consumption of GSH that is not matched by an equal in 
the rate of synthesis of the tripeptide.       
Gil et al. (2003) showed both a reduction of GSH levels and an increased in MDA and total 
hydroperoxides levels were detected in the plasma of HIV-1 seropositive individuals. These 
patients also showed an increase of DNA fragmentation in lymphocytes, reduction of 
glutathione peroxidase, and an increase in SOD activity in erythrocytes. There are several 
studies of disturbed GSH metabolism in HIV-1 infected patients. Arkrust et al. (2003) 
showed that, during HAART, the decrease in virus load and the increase in CD4+ T cell 
count are accompanied by both an improvement in the abnormal GSH-redox status and an 
increase in the subnormal levels of antioxidant vitamins. They have shown that HIV-1 
infected patients are characterized by a decrease in both reduced GSH and vitamin C, the 
two most important hydrophilic antioxidants. 
HIV-1 infection results in considerably reduced ǂ-tocopherol concentrations and very low 
plasma zinc and selenium levels. Zinc and copper ions inhibit intracellular HIV-1 
replication (Sprietsma, 1997). The precise mechanism by which the antioxidant effects of 
zinc is accomplished stems from its involvement in SOD and other enzymatic process. In 
humans, marked zinc deficiency strongly compromises the immune function and often 
enhances vulnerability to fatal opportunistic infections. It decreases CD4+ T helper cell 
function, CD8+ T cell cytotoxic activity, serum thymulin activity, and the interleukin-2 (IL-
2) production by peripheral blood mononuclear cells. It also reduces the natural killer 
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cells lytic activity, DNA repair, the antibodies formation, and macrophage and 
neuthrophil function. In experimental and human models, the zinc deficiency caused an 
imbalance between Th1 and Th2 functions resulting in decreased production of IFN-. 
These specific effects on T cell proliferation and function are not duplicated by other 
micronutrients (Stehbens, 2004).   
Selenium deficiency diminishes cell-mediated immunity and depresses B-cell function, and 
it is associated with the occurrence, virulence, and disease progression to overt AIDS 
(Stehbens, 2004). Apoptosis of the cells is fundamental to progression of the disease that 
correlates with the decrease in plasma zinc, selenium, and vitamin E (Farvier et al., 1994).  
Many antioxidants have been tried for AIDS therapy including selenium, vitamin C, vitamin 
E, lipoic acid,  carotene, whey proteins, and the epigallocatechin gallate (EGCG), the major 
component of green tee. 
However, there are conflicting reports in the values of antioxidant vitamin E and vitamin C 
and SOD enzyme activity among HIV-1 infected patients in various stages in the literature 
(Allard et al., 1998; Stambullian et al., 2007). Suresh et al. (2009) showed that vitamin E, 
vitamin C, SOD, and TAC levels are decreased in HIV-1 patients, and the depletion was 
pronounced in HIV-1 symptomatic compared to HIV-1 asymptomatic individuals, in 
contrast to previous studies where were no significant differences in antioxidant vitamins in 
both groups (Allard et al., 1998).   
McDermid et al. (2002) investigated the relation between dietary antioxidant intake and 
oxidative stress in clinically stable HIV-1 positive and HIV-1 negative adults. The results 
suggested dietary selenium intake was strongly and inversely associated with plasma MDA, 
but dietary antioxidant intakes were not related to peripheral blood mononuclear cell GSH 
concentration.  
Total antioxidant status has been reduced in HIV-1 infected patients, probably due 
depletion of antioxidant molecules when they are consumed in the process of protecting 
cells against ROS induced oxidative damage in a magnitude that is related to advancement 
of the disease to AIDS (Ogunro et al., 2005). 
Endothelial dysfunction induced by HIV-1 PIs may possible be reversed by antioxidants, 
including ginsenosides, selenium, curcumin (Chai et al., 2005a; Chai et al., 2005b), and 
resveratrol (Touzet & Philips, 2010). Therefore, it has been proposed by some researches that 
the oxidative stress and antioxidant status of HIV-1 seropositive patients could be 
monitored periodically during the disease progression. The possibility of counteracting 
oxidative stress by a pool of proper antioxidant plus an appropriate diet, mainly in patients 
whose blood antioxidant deficiencies can be easily rebalanced may have real health benefit 
and represent a promising way of inhibiting the progression of disease. 
A new class of non-peptidic macrocyclic (MnII) complexes that possesses SOD enzymatic 
activity has been synthesized, which has the same activity as native SOD but can 
significantly cross the BBB (Salvemini et al., 1999).  A SOD mimetic complex has been shown 
to significantly protect against the apoptotic cell death that occurs in astroglia that was 
incubated with supernatants of HIV-1 infected human macrophages. This effect was 
accompanied by a reduction of MDA concentration in astroglial cells and by a reduction of 
nitrotyrosine staining in these cells, showing that the effect of this mimetic complex 
occurred via reduction of ROS formation, and in turn, could reduce the neurodegenerative 
processes that occur in neuroAIDS (Mollace et al., 2001).  
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Many clinical trials on HIV-1 dementia have centered on drugs that block receptors or are 
antagonists to the neurotoxic chemokines and cytokines released from activated microglia, 
macrophages, and astrocytes. These drugs, including nimodipine (L-type calcium channel 
antagonist), peptide T (possible chemokine receptor blocker), selegiline and deprenyl 
(monoamine oxidase-B inhibitors), lexipafant (platelet-activating factor antagonist), and 
CPI-1189 (TNF antagonist), indirectly act as antioxidants by blocking the downstream 
effects of these neurotoxic agents that usually result in an increase of ROS, RNS, and 
neuronal death (Turchan et al., 2003).     
The importance of micronutrients in the prevention and treatment of childhood infections is 
well known, and evidence is emerging that micronutrient interventions may also affect HIV-
1 transmission and progression. To clarify this issue, Friis (2006) reviewed evidences on the 
role of micronutrient supplementation in HIV-1 transmission and progression. The author 
concluded that interventions to improve micronutrient intake and status could contribute to 
a reduction in the magnitude and impact of the global HIV-1 epidemic. However, more 
research is needed before specific recommendations can be made. Fawzi et al (2005) 
underscored that poor nutrition and HIV-1 related adverse health outcomes contribute to a 
vicious cycle that may be slowed down by using nutritional interventions, including 
vitamins and minerals. Among children, periodic supplementation with vitamin A starting 
at six months of age has been shown to be beneficial in reducing mortality and morbidity 
among both HIV-1-infected and uninfected children. Limited data exist on the role of other 
nutrient supplements among children. Among HIV-1 infected adults, the safety and the 
efficacy of vitamin A supplements need further study, although adequate dietary intake of 
this essential nutrient is recommended. Multivitamin supplements were efficacious in 
reducing adverse pregnancy outcomes and early childhood infections, and is currently 
provided to HIV-1 infected pregnant women in many programs. The efficacy of such 
supplements among HIV-1 negative pregnant women needs further study. Daily 
multivitamin supplements were found to reduce HIV-1 disease progression among men and 
women and could be provided to adults in early stages of HIV-1 disease to prolong the time 
before antiretroviral therapy. 
In order to assess whether micronutrient supplements are effective and safe in reducing 
mortality and morbidity in adults and children with HIV-1 infection, 30 randomized 
controlled trials were selected that compared the effects of micronutrient supplements 
(vitamins, trace elements, and combinations of these) with other supplements, placebo or no 
treatment on mortality, morbidity, pregnancy outcomes, immunologic indicators, and 
anthropometric measures in HIV-1 infected adults and children (Irlam et al, 2005, 2010). Any 
adverse effects of supplementation were recorded in 30 trials involving 22,120 participants: 20 
trials of single supplements (vitamin A, vitamin D, zinc, selenium) and 10 of multiple 
micronutrients. Eight trials were undertaken in child populations. The results of this meta-
analysis showed that multiple micronutrient supplements reduced morbidity and mortality in 
HIV-1 infected pregnant women and their offspring and also improved early child growth in 
one large randomized controlled trial in Africa. Additional research is needed to determine if 
these are generalisable findings. Vitamin A supplementation is beneficial and safe in HIV-1 
infected children, but further evidence is needed to establish if supplementation confers 
similar benefits in HIV-1 infected adults. Zinc is safe in HIV-1 infected adults and children. It 
may have similar benefits in HIV-1 infected children and adults, and uninfected children with 
diarrhea, as it does in HIV-1 uninfected children. Further trials of single supplements (vitamin 
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D, zinc, and selenium) are required to build the evidence base. The long-term clinical benefits, 
adverse effects, and optimal formulation of multiple micronutrient supplements require 
further investigation in individuals with diverse disease status.  
The exogenous supply of antioxidants using novel and more-specific molecules that 
scavenge free radical might allow further advances in understanding the processes that 
underlie the pathogenesis of HIV-1 infection and thus might represent the basis for novel 
and potentially efficient strategies in the complementary treatment of neurological, 
endothelium, and cardiovascular diseases associated with the HIV-1 infection. 
9. Conclusion 
There is clear evidence that the gp120 and Tat HIV-1 proteins and antiretroviral drugs 
directly and indirectly induce oxidative stress. Damage-induced by oxidative stress in 
endothelial cells and neurons may be correlated with an increase in the risk of 
cardiovascular disease and dementia, respectively, in HIV-1 infected patients. Although 
differences may exists to the relative contribution and mechanisms of toxicity, the 
preponderance of clinical and experimental data suggest roles for both of these factors in the 
context of HIV-1 infection. In assessing cardiovascular risk, it is important to take into 
account potential contributions from both infection and therapy. To various degrees, 
multiple HIV-1 viral proteins and antiretroviral drugs activate cell signaling cascades, 
induce oxidative stress, disturb mitochondrial function, alter gene expression, and impair 
lipid metabolism. These changes occur in endothelial cells, in vascular muscle cells, 
macrophages, adipocytes, and in neuronal cells.  
The main changes that have been reported by in vivo and in vitro studies are the increase of 
the LPO, protein oxidation, and NO metabolites, decrease in the individual antioxidants 
defenses such as vitamin C, vitamin E, GSH, catalase, selenium, and zinc. In addition, the 
total status antioxidant is also impaired in HIV-1 infected individuals. NO cannot be rigidly 
classified as an anti-inflammatory or pro-inflammatory molecule, but it can be considered a 
true inflammatory mediator. It has been also reported that oxidative stress in HIV-1 infected 
individuals is associated with increase of DNA fragmentation in lymphocytes, reduction of 
glutathione peroxidase, and an increase in SOD activity in erythrocytes.      
The better knowledge of the ways in which HIV-1 proteins and antiretroviral drugs interact 
with each other and with the host cells, mainly the endothelial, the neuronal, and immune 
system cells, may contribute to discover new approaches to be associated with the 
antiretroviral therapies in order to prevent cardiovascular  diseases and neurological 
disorders in HIV-1 infected individuals. 
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